Up-regulation of IFN-stimulated genes (ISGs) is sustained in hepatitis C virus (HCV)-infected livers. Here, we investigated the mechanism of prolonged ISG expression and its role in IFN responsiveness during HCV infection in relation to unphosphorylated IFN-stimulated gene factor 3 (U-ISGF3), recently identified as a tripartite transcription factor formed by high levels of IFN response factor 9 (IRF9), STAT1, and STAT2 without tyrosine phosphorylation of the STATs. The level of U-ISGF3, but not tyrosine phosphorylated STAT1, is significantly elevated in response to IFN-λ and IFN-β during chronic HCV infection. U-ISGF3 prolongs the expression of a subset of ISGs and restricts HCV chronic replication. However, paradoxically, high levels of U-ISGF3 also confer unresponsiveness to IFN-α therapy. As a mechanism of U-ISGF3-induced resistance to IFN-α, we found that ISG15, a U-ISGF3-induced protein, sustains the abundance of ubiquitin-specific protease 18 (USP18), a negative regulator of IFN signaling. Our data demonstrate that U-ISGF3 induced by IFN-λs and -β drives prolonged expression of a set of ISGs, leading to chronic activation of innate responses and conferring a lack of response to IFN-α in HCVinfected liver.
Up-regulation of IFN-stimulated genes (ISGs) is sustained in hepatitis C virus (HCV)-infected livers. Here, we investigated the mechanism of prolonged ISG expression and its role in IFN responsiveness during HCV infection in relation to unphosphorylated IFN-stimulated gene factor 3 (U-ISGF3), recently identified as a tripartite transcription factor formed by high levels of IFN response factor 9 (IRF9), STAT1, and STAT2 without tyrosine phosphorylation of the STATs. The level of U-ISGF3, but not tyrosine phosphorylated STAT1, is significantly elevated in response to IFN-λ and IFN-β during chronic HCV infection. U-ISGF3 prolongs the expression of a subset of ISGs and restricts HCV chronic replication. However, paradoxically, high levels of U-ISGF3 also confer unresponsiveness to IFN-α therapy. As a mechanism of U-ISGF3-induced resistance to IFN-α, we found that ISG15, a U-ISGF3-induced protein, sustains the abundance of ubiquitin-specific protease 18 (USP18), a negative regulator of IFN signaling. Our data demonstrate that U-ISGF3 induced by IFN-λs and -β drives prolonged expression of a set of ISGs, leading to chronic activation of innate responses and conferring a lack of response to IFN-α in HCVinfected liver.
hepatitis C virus | U-ISGF3 | interferon | interferon-stimulated genes H epatitis C virus (HCV) infection tends to progress to chronic hepatitis. Acute HCV infection is spontaneously cleared in 20-30% of patients, but the majority of patients fail to clear the virus and develop a chronic persistent infection (1) . Type I IFNbased regimens have been the standard therapy against HCV. Type I IFNs are antiviral cytokines that induce the expression of numerous IFN-stimulated genes (ISGs), many of which exert antiviral activities and suppress viral replication (2) .
Recently, it was demonstrated that type III IFNs, also known as IFN-λs (IFN-λ 1 or IL-29; -λ 2 or IL-28A; and -λ 3 or IL-28B), are a major type of IFNs produced by HCV-infected hepatocytes (3) (4) (5) (6) . The production of type III IFNs by HCV-infected hepatocytes results in the expression of ISGs, presumably through autocrine and/or paracrine signaling via the IFN-λ receptor (4) (5) (6) . Recent study using a highly sensitive in situ hybridization system revealed that ISG mRNAs are increased and enriched in HCV-infected and adjacent cells (7) . This finding suggests that HCV infection potently stimulates the production of endogenous IFNs, leading to ISG up-regulation in infected livers (7, 8) . Indeed, continuous ISG up-regulation in HCV-infected livers has been demonstrated in chimpanzee models (9, 10) and HCV-infected human livers (11, 12) .
In patients with chronic HCV infection, it has been demonstrated that those with high levels of ISGs in the liver at baseline respond poorly to pegylated IFN-α (peg-IFN-α)/ribavirin therapy (11) (12) (13) (14) (15) (16) . In particular, the baseline levels of ISG15, IFI27, IFI44, Mx1, and OAS1 could predict a poor response to the peg-IFN-α/ribavirin therapy (11, 12, 16) . In addition, ubiquitin-specific protease 18 (USP18), which can block tyrosine-phosphorylation of signal transducers and activators of transcriptions (STATs) (17) , is up-regulated in HCV-infected livers, and its expression level is higher in patients who do not respond to peg-IFN-α/ribavirin therapy (12). However, how the level of USP18 is increased and maintained in HCV-infected livers has not been clearly elucidated.
Binding of type I IFNs to their receptor leads to the activation of the intracellular Janus kinases JAK1 and TYK2. Next, STATs 1 and 2 are phosphorylated on their C-terminal tyrosine residues, and PY-STAT1 and PY-STAT2 then form a tripartite transcription factor with IFN response factor 9 (IRF9). This transcription factor, IFN-stimulated gene factor 3 (ISGF3), induces the expression of hundreds of ISGs (18, 19) . Type III IFNs activate the same JAK-STAT pathway (20) , inducing similar sets of ISGs, although the kinetics and intensity of these responses may differ in human hepatocytes (21, 22) .
After cells are stimulated by type I IFNs, ISGF3 induces the initial response, but the related factor unphosphorylated ISGF3 (U-ISGF3), formed by high levels of IRF9, unphosphorylated STAT1 (U-STAT1), and unphosphorylated STAT2 (U-STAT2), drives a second, delayed response, inducing a subset of downstream ISGs (23) (24) (25) . In a previous report, we showed that continuous exposure of cells to a low level of exogenous IFN-β led to prolonged up-regulation of only the U-ISGF3-induced ISGs (U-ISGs) (24) . The IFN-stimulated response element sequences of the U-ISGs were distinct from the sequences of the ISGs induced by phosphorylated ISGF3 but not by U-ISGF3 (24) . However, it has not been proven whether IFN-λs also lead to induction of U-ISGF3 and U-ISGs.
Significance
Hepatitis C virus (HCV) infection stimulates the production of endogenous interferons (IFNs) and the following persistent activation of interferon-stimulated genes (ISGs) in the infected liver. In the patients with chronic HCV infection, high levels of activated ISGs in the liver at baseline were proved to predict poor response to pegylated IFN-α/ribavirin therapy. In this report, we demonstrate that the level of unphosphorylated IFNstimulated gene factor 3 (U-ISGF3), not ISGF3, is increased by endogenous IFN-λs and IFN-β in HCV-infected hepatocytes and livers, leading to persistent activation of a set of ISGs. We also demonstrate that the high level of ISG15 induced by U-ISGF3 resulted in an increased level of ubiquitin-specific protease 18 (USP18), a critical negative regulator of the response to exogenous IFN-α.
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The authors declare no conflict of interest. In the present study, we investigated the mechanism of persistent expression of ISGs in HCV-infected cells and the mechanism of IFN-α unresponsiveness in relation to U-ISGF3, using in vitro HCV infection systems and HCV-infected human liver tissues. In summary, HCV-infected hepatocytes produced substantial amounts of IFN-λs and a small amount of IFN-β, and continuous stimulation of hepatocytes by these IFNs increased the levels of IRF9, STAT1, and STAT2 without tyrosine phosphorylation and prolonged the expression of U-ISGs, including ISG15. The high level of ISG15 induced by U-ISGF3 resulted in an increased level of USP18, a critical negative regulator of the response to exogenous IFN-α.
Results
Increased Expression of STAT1, STAT2, and IRF9 Without PY-STAT1 in Liver Tissues of Patients with Chronic HCV Infection. First, we examined the expression of the U-ISGF3 components and U-ISGs in liver tissues from patients with chronic HCV infections. Using immunoblotting, higher levels of STAT1, STAT2, and IRF9 were observed in HCV-infected livers than in control livers whereas STAT1 phosphorylated on Y701 (PY-STAT1) was present at only low levels or not detected at all even after long exposure of immunoblots of HCV-infected livers (Fig. 1A) . In contrast, the levels of STAT1, STAT2, and IRF9 were not increased in hepatitis B virus (HBV)-infected liver tissues (Fig. 1B) . The expression of U-ISGs, such as Mx1, OAS1, and ISG15 (24) , was up-regulated in HCV-infected livers (Fig. 1C ) whereas the expression of MyD88, ADAR, and IRF1, ISGs known to be driven only by phosphorylated ISGF3 (24), was not increased in HCV-infected livers (Fig. 1D) . Collectively, these data indicate that the levels of U-ISGF3 and U-ISGs are increased in HCV-infected livers.
HCV Infection Increases the Levels of U-ISGF3 and U-ISGs. We verified the results obtained for HCV-infected livers by studying primary human hepatocytes (PHHs) infected with cell culture-derived HCV (JFH1 HCVcc; genotype 2a). Highly permissive PHHs were selected and used for this experiment. As observed in HCV-infected livers, the levels of STAT1, STAT2, and IRF9 increased after HCV infection whereas PY-STAT1 was barely observable in HCV-infected cells ( Fig. 2A) . Moreover, U-ISGs were robustly increased in HCV-infected cells, including Mx1, OAS1, and OAS2 (Fig. 2B ). By contrast, ISGF3-dependent ISGs were not induced (MyD88 and ADAR in Fig. 2C ) or were minimally induced (IRF1 in Fig. 2C ) in HCV-infected cells. These findings were also confirmed by HCVcc infection of Huh-7 cells transduced with the TLR3 gene (Huh-7-TLR3). The levels of STAT1, STAT2, and IRF9 increased since 48 h after HCV infection. In contrast, PY-STAT1 was observed only on the first day of HCV infection ( Fig. 2D ). U-ISGs (24) were robustly upregulated in HCV-infected Huh-7-TLR3 cells. However, ISGs known to be induced only by phosphorylated ISGF3 (24) were barely increased (Fig. 2E ) although all of the examined ISGs were up-regulated by exogenous IFN-β treatment (Fig. S1 ).
Detection of U-ISGF3 Components in the Nuclei of HCV-Infected Cells
and Their Binding to the Promoter Regions of ISGs. Cell lysates were fractionated into nuclei and cytoplasm after HCV infection. Increased levels of STAT1, STAT2, and IRF9 were observed in the nuclear fractions of HCV-infected cells whereas PY-STAT1 was not detected without exogenous IFN-β treatment (Fig. 3A) . Immunohistochemical staining also showed nuclear enrichment of STAT1 in HCV-infected livers, but PY-STAT1 was barely detected in HCV-infected livers (Fig. 3B ). Chromatin immunoprecipitation (ChIP) assays were performed using HCV-infected cells, and we found that all three components of U-ISGF3 bound to the promoter regions of U-ISGs, such as Mx1 and IFI27 (24), but not to those of MyD88 and IRF1, which are known to be regulated only by ISGF3 (24) (Fig. 3C ). For positive controls, ChIP assays were performed using the PY-STAT1 antibody in IFN-β-treated, HCV-infected Huh-7-TLR3 cells (Fig. S2 ). ChIP assays were also performed using HCV-infected liver tissues (Fig. 3D ). IRF9 bound to the promoter region of Mx1, but PY-STAT1 did not. In the case of MyD88, neither IRF9 nor PY-STAT1 bound to the promoter region in HCV-infected liver tissues. Collectively, these data suggest that U-ISGF3 is present in the nuclei and directly regulates the expression of U-ISGs in HCV-infected cells.
Induction of U-ISGs by High Levels of STAT1, STAT2, and IRF9 Without IFN Stimulation. Y701F-STAT1 is a mutant STAT1 that cannot be phosphorylated on Y701, blocking access of the WT STAT1 to the receptor (26) . To clarify the mechanism of U-ISGF3 in the induction of U-ISGs, we overexpressed Y701F-STAT1, STAT2, and IRF9 in Huh-7.5 cells by lentiviral gene transduction without exogenous IFN treatment (Fig. 4A) . Of note, Huh-7.5 cells express substantial levels of STAT1 and STAT2 but not IRF9 at baseline (Fig. 4A) . The expression of U-ISGs was also examined. The expression of Mx1 and OAS1 was not increased by overexpression of Y701F-STAT1 and STAT2, but their expression was increased by overexpression of IRF9 (Fig. S3) , which was anticipated because Huh-7.5 cells express a very low level of IRF9 (Fig. 4A) . Moreover, combined high expression of IRF9, Y701F-STAT1, and STAT2 further increased the expression of Mx1 and OAS1 (Fig. S3) .
We further examined the expression of additional ISGs after overexpression of Y701F-STAT1, STAT2, and IRF9 together. U-ISGs (ISG15, BST2, and MAP3K) were up-regulated after overexpression of these proteins (Fig. 4B ), but genes regulated only by phosphorylated ISGF3 (ADAR, PKR, and CXCL16) were not (Fig. 4C) . Finally, we overexpressed Y701F-STAT1, STAT2, and IRF9 in HCV (genotype 1a) replicon cells and found that the overexpression of these proteins decreased the HCV RNA titer (Fig. 4D) . Collectively, these data show that, in human liver-derived cells, high levels of the U-ISGF3 components induce the expression of U-ISGs, which exert antiviral functions, without exogenous IFN treatment.
Endogenous Type I and III IFNs Induce U-ISGF3 and U-ISGs in HCVInfected Cells. Next, we attempted to examine which IFNs induced U-ISGF3 in HCV-infected cells. We observed robust production of IFN-λs, rather than IFN-β, in HCV-infected PHHs (Fig. S4A) and HCV-infected Huh-7-TLR3 cells (Fig.  S4B) , confirming previous reports (3) (4) (5) (6) .
We investigated whether IFN-λs also induced high levels of the U-ISGF3 components and prolonged expression of U-ISGs, similarly to IFN-β (24). We treated Huh-7.5 cells with recombinant IFN-β and IFN-λs for up to 72 h, finding that the levels of STAT1, STAT2, and IRF9 were increased not only by IFN-β (Fig.  S5A), but also by IFN-λs (Fig. S5B) . PY-STAT1 and PY-STAT2 disappeared 12 h after IFN treatment, but the levels of STAT1, STAT2, and IRF9 remained high even after 72 h. After IFN-β treatment, ISGs regulated by ISGF3 (MyD88 and IRF1) showed early induction without delayed response (Fig. S5C) . In contrast, U-ISGs (Mx1 and OAS1) showed sustained responses after IFN-β treatment (Fig. S5C) . Compared with IFN-β, the tyrosine phosphorylation of STAT1 and STAT2 induced by all three types of IFN-λs was relatively weak, but U-ISGF3 was robustly induced by IFN-λs (Fig. S5B) . Accordingly, the expression of ISGF3-dependent ISGs was marginally induced, but the U-ISGs were robustly induced after IFN-λ treatment in a delayed manner (Fig.  S5D) . These data were corroborated in the experiment using other liver-derived cells including PHHs, differentiated HepaRG cells, and HepG2 cells (Fig. S6) . These liver-derived cells expressed considerable levels of IFNAR1 and IFNLR1 mRNAs (Fig. S7) .
Ultimately, we blocked the effect of endogenous IFN-λs or IFN-β with neutralizing antibodies in cultures of HCV-infected Huh-7-TLR3 cells, finding that the induction of U-ISGF3 components was abrogated by either blocking antibody (Fig. 5A) . In addition, the induction of U-ISGs, such as Mx1 and OAS1, was also abrogated by blocking antibodies to either IFN-λs or IFN-β (Fig. 5B) . Intriguingly, IFN-β blockade also reduced the production of IFN-λs in cultures of HCV-infected Huh-7-TLR3 cells ( 
The Expression of ISG15 and USP18 Proteins Is Increased by Prolonged
Exposure of Cells to Type III IFNs and in HCV-Infected Livers. It has been reported that high basal levels of some ISGs, mostly known as U-ISGs, correlate with poor response to peg-IFN-α/ribavirin therapy (11) (12) (13) (14) (15) . As a mechanism of the unresponsiveness to IFN-α, we further investigated ISG15, one of the U-ISGs. ISG15 was recently shown to regulate the stability of the USP18 protein by preventing its ubiquitination (27) , and USP18 is a well-known negative regulator of IFN-α signaling. We hypothesized that prolonged stimulation with IFN-λ induces U-ISGF3 and U-ISGs, including ISG15, and that subsequent stabilization of USP18 by ISG15 confers lack of response to exogenous IFN-α. Indeed, prolonged exposure to IFN-λ 3 induced high levels of the U-ISGF3 components, but IFN-λ 3 -pretreated cells showed much weaker phosphorylation of STAT1 after treatment with exogenous IFN-α or peg-IFN-α2b than did control cells (Fig. 6A) . Accordingly, the increase in ISG expression was far less in response to peg-IFN-α2b in IFN-λ 3 -pretreated cells (Fig. 6B) . However, attenuated responses in STAT1 phosphorylation and ISG induction were not observed after treatment with exogenous IFN-β or IFN-λ 1 in IFN-λ 3 -pretreated cells (Fig. S8) . We also investigated the expression of ISG15 and USP18. In line with our hypothesis, ISG15 protein and mRNA levels were both increased in IFN-λ 3 -treated cells, but USP18 was increased only at the protein level (Fig. 6 C and D) . Moreover, silencing of ISG15 decreased the protein level of USP18 in IFN-λ 3 -treated cells (Fig. 6E) . Immunoblotting of ISG15 and USP18 in extract of HCV-infected livers showed that both ISG15 and USP18 were increased in HCV-infected livers (Fig. 6 F and G) and that the level of ISG15 was correlated with the level of USP18 in HCVinfected livers (Fig. 6H) . These data mean that ISG15, one of the U-ISGs, regulates USP18 at the protein level and is likely to mediate the lack of response to exogenous IFN-α in IFN-λ 3 -pretreated cells and HCV-infected livers. 3 . In control siRNA-transfected, IFN-λ 3 -pretreated cells, the phosphorylation of STAT1 induced by peg-IFN-α2b was attenuated (Fig. 7A) . However, STAT1 phosphorylation was restored by transfection of USP18 siRNA (Fig. 7A) . Transfection of ISG15 siRNA resulted in a decreased level of USP18, and phosphorylation of STAT1 was also restored (Fig. 7A) . Moreover, peg-IFNα2b-induced ISG expression was partly restored by transfection of USP18 or ISG15 siRNA and was restored even more by transfection of USP18 and ISG15 siRNAs in combination (Fig. 7B) . explain why ISG expression is sustained in HCV-infected livers and why high basal levels of ISGs in the liver correlate with poor responses to IFN-α-based therapy in HCV-infected patients. Recently, the effects of peg-IFN-α administration on STAT phosphorylation and ISG expression were studied using paired liver biopsy samples from patients with chronic HCV infection (28) . In that study, peg-IFN-α administration resulted in prolonged expression of a subset of ISGs in HCV-infected livers although STAT1 was only transiently phosphorylated (28) . Those data indicate that U-ISGF3 might play important roles in inducing ISGs at late time in response to peg-IFN-α. However, a role for U-STAT1 was apparently ruled out by a simple transfection experiment in that study (28) . The authors transfected WT or Y701F-STAT1 into STAT1-deficient U3A cells, which were derived from 2fTGH cells. The STAT1 protein levels were higher in the STAT1-transfected U3A cells, compared with endogenous STAT1 protein levels in parental 2fTGH cells, and the OAS1 expression in STAT1-transfected U3A cells was not higher than in 2fTGH cells. Based on these data, the authors concluded that U-STAT1 cannot induce ISGs (28) . But U-STAT1 can induce a subset of ISGs only when the cells express sufficient levels of other two component proteins, STAT2 and IRF9 (24) . In BJ fibroblasts that express high levels of STAT2 and IRF9, overexpression of STAT1 alone can induce U-ISGs (25) . However, hTERT-HME1 cells, which express a very low basal level of IRF9 and STAT2, expressed U-ISGs only after transfection of both IRF9 and STAT2, not after transfection of STAT1 alone (24) . The Huh-7.5 cells used in the current study express a very low basal level of IRF9 (Fig. 4A) , so that the expression of Mx1 and OAS1 was increased by transfection of IRF9, and not by transfection of STAT1 (Fig. S3) . Furthermore, the combined transfection of IRF9, Y701F-STAT1, and STAT2 together drove a more prominent increase in U-ISGs induction in Huh-7.5 cells (Fig. S3 ) and STAT1-null fibroblasts (24) . These data indicate that all of the three components of U-ISGF3, rather than U-STAT1 alone, are required for the induction of U-ISGs. In addition, U3A cells were isolated after extensive chemical mutagenesis (29) , and those cells surely harbor many unknown defects, as well as the lack of STAT1 expression. We observed that U3A cells have defects in inducing many ISGs in response to IFN-β and IFN-γ even after transfection with WT STAT1 (Fig.  S9) . We find that the previous conclusion by Dill et al. (28) from an experiment in which STAT1 was reexpressed in U3A cells cannot be used as an evidence to deny a role for U-ISGF3 in ISG induction.
Discussion
Some patients with chronic HCV infections express a high basal level of ISGs in their infected livers (11) (12) (13) 16 ) and respond poorly to peg-IFN-α/ribavirin therapy (11) (12) (13) (14) (15) (16) . In particular, the basal levels of ISG15, IFI27, IFI44, Mx1, and OAS1 could be used to predict a poor response to this therapy (11, 12, 16) . Interestingly, these ISGs are known to be regulated by U-ISGF3 (24) . Considering that the IFNs produced by HCV infection are mainly IFN-λs, which elicit a weak initial response through ISGF3 but a robust and prolonged response through U-ISGF3 (Fig. S5) hepatocytes. Indeed, our analyses of HCV-infected liver tissues showed that PY-STAT1 was barely detected whereas the components of U-ISGF3 and U-ISGs were maintained at high levels.
In the last part of the present study, we investigated how U-ISGF3 results in the poor response to IFN-α treatment, finding that ISG15, one of the U-ISGs, is responsible. ISG15 stabilizes USP18 protein by preventing its ubiquitination (27) , and USP18 blocks the phosphorylation of STAT1 and STAT2 at the level of the receptor-kinase complex (17, (30) (31) (32) (33) . Thus, ISG15 hampers the type I IFN response (27) . In the current study, ISG15 was upregulated in cells with prolonged IFN-λ 3 stimulation (Fig. 6 C  and D) or in HCV-infected livers (Figs. 1C and 6F) as a U-ISG (Fig. 4B) . In the case of USP18, the protein level increased in cells upon prolonged IFN-λ 3 stimulation (Fig. 6C ) or in HCVinfected livers (Fig. 6F) . Intriguingly, silencing of ISG15 expression decreased the protein level of USP18 in cells exposed to prolonged IFN-λ3 stimulation (Fig. 6E) and increased the response to peg-IFN-α (Fig. 7 A and B) . Collectively, we showed that, in HCV-infected livers, the basal expression of U-ISGF3-dependent ISG15 is critical in regulating the subsequent IFN-α response by regulating the abundance of USP18 protein.
In conclusion, we demonstrate that the level of U-ISGF3 is increased by endogenous IFN-λs and IFN-β in HCV-infected hepatocytes and livers. The induced U-ISGF3 causes sustained expression of U-ISGs, contributing to a poor response to IFN-α-based therapy via increased expression of ISG15 and USP18.
Materials and Methods
Detailed materials and methods can be found in SI Materials and Methods. Huh-7-TLR3 cells were generated by transduction of Huh-7 cells with lentivirus harboring the pLenti-CMV-hTLR3 vector. The function of TLR3 protein in Huh-7-TLR3 cells was confirmed by the experiment demonstrating the ability to produce IFN-λ after poly I:C stimulation. Hepatitis virus-infected, nontumorous liver tissues were obtained from eight patients with HCV-associated hepatocellular carcinoma (HCC) and eight patients with HBV-associated HCC through the National Biobank of Korea [Pusan National University Hospital (PNUH), Busan, Korea]. Six liver tissues without viral hepatitis were also obtained during surgical procedures such as cholecystectomy, adrenalectomy, and partial liver resection for intrahepatic duct stones at Daejeon St. Mary's Hospital (Daejeon, Korea). The procedure was permitted by the approval of the institutional review board of Daejeon St. Mary's Hospital and Korea Advanced Institute of Science and Technology and the agreement of the patients.
